INSM

Insmed Incorporated [INSM] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INSM Stock Summary

Top INSM Correlated Resources

INSM

Top 10 Correlated ETFs

INSM

Top 10 Correlated Stocks

INSM

In the News

INSM Financial details

Company Rating
-
Market Cap
4.05B
Income
-749.57M
Revenue
305.21M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
912
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-5.34
Forward P/E
-
PEG
-1.46
P/S
13.46
P/B
-12.07
P/C
-
P/FCF
-7.47
Quick Ratio
3.64
Current Ratio
4.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.34
EPS next Y
-
EPS next Q
-
EPS this Y
36.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.15%
Revenue last 5Y
17.47%
Revenue Q/Q
5.84%
EPS Q/Q
15.32%
-
-
-
-
SMA20
9.23%
SMA50
8.22%
SMA100
10.29%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
365%
ROC
-0.65%
Gross Margin
79%
Oper. Margin
-236%
Profit Margin
-246%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.46-32.0
52W High
+153.31%
52W Low
+406.63%
RSI
58.18
Rel Volume
1.66
Avg Volume
1.63M
Volume
2.7M
Perf Week
1.46%
Perf Month
22.61%
Perf Quarter
5.92%
Perf Half Y
5.26%
-
-
-
-
Beta
0.915
-
-
Volatility
1.9%, 4.86%
Prev Close
-3.05%
Price
81.06
Change
1.2%

Something similar

Top by Market Cap
AVGO
BRK-A
VFINX
META
ABEC.DE
Top Correlated ETFs
OVT
JDIV
QUS
IWX
DIVB
Top Correlated Stocks
0JAV.L
NNI
MTTR
KALV
BPYPN
Similar Market Cap
T6A.DE
1598.TW
SMMCX
002212.SZ
RVRC.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 1.63M
  • Market Capitalization 4.05B
  • Employee 912
  • CEO Mr. William H. Lewis J.D., M.B.A.
  • Headquarters Bridgewater,NJ,US
  • IPO Date 2000-06-01
  • Website https://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.